Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
Company Expects Total Revenue Growth of 23% to 26% for Q2 2017 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced
View HTML
Toggle Summary Anika Announces $50 Million Share Repurchase Program
BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that its Board of Directors has
View HTML
Toggle Summary Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
Board Chair Joseph Bower ,   D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board BEDFORD, Mass. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation,
View HTML
Toggle Summary Anika Announces Appointment of Joseph Darling as President
Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
Deep international expertise to drive the Company's global expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress
BEDFORD, Mass. & VIENNA --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to present Phase III data on CINGAL ® , its novel
View HTML
Toggle Summary Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society
-- Podium Sessions Showcase Studies Comparing HYALOFAST versus Collagen Scaffold and Microfracture Surgery for Cartilage Repair -- BEDFORD, Mass. & NAPLES, Italy --(BUSINESS WIRE)-- Anika Therapeutics, Inc. , ( NASDAQ : ANIK), a global, integrated orthopedics medicines company specializing in
View HTML
Toggle Summary Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. , ( NASDAQ : ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the commercial launch of CINGAL ® , its third-generation
View HTML
Toggle Summary Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from
View HTML
Toggle Summary Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints
System designed to alleviate pain and restore function and mobility of the wrist joint BEDFORD, Mass. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic
View HTML